Drug Profile


Alternative Names: Anatabine citrate; Controlled release; RCP-006

Latest Information Update: 19 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Star Scientific
  • Developer Rock Creek Pharmaceuticals Inc; Roskamp Institute; Zenith Technology Corporation
  • Class Alkaloids; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Cholinergic receptor agonists; Glycogen synthase kinase 3 beta inhibitors; NF-kappa B inhibitors; STAT3 transcription factor inhibitors; STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Inflammation; Neurological disorders
  • Preclinical Brain injuries; Cognition disorders; Multiple sclerosis; Osteoarthritis; Psoriasis; Smoking withdrawal; Thyroiditis; Ulcerative colitis

Most Recent Events

  • 16 May 2016 Rock Creek Pharmaceuticals plans a phase IIa/II trial in Psoriasis (Topical)
  • 05 May 2016 Rock Creek Pharmaceuticals receives patent allowance for anatabine in Japan
  • 13 Apr 2016 Rock Creek Pharmaceuticals has patent protection for anatabine in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top